CORONA Remedies Limited Stock Price Today (NSE: CORONA)
Fundamental Score
CORONA Remedies Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
CORONA Remedies Limited share price today is ₹2181.50, down 1.42% on NSE/BSE as of 22 September 2026. CORONA Remedies Limited (CORONA) is a Mid-cap company in the Unknown Industry sector with a market capitalisation of ₹13.34K (Cr). The 52-week high for CORONA share price is ₹2292.40 and the 52-week low is ₹2020.20.
CORONA Remedies Limited Share Price Chart — NSE/BSE Historical Performance
CORONA Remedies Limited share price chart: -0.94% return over the past month. 52-week high ₹2292.40, 52-week low ₹2020.20.
CORONA Remedies Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹2175.00 | ₹2208.00 | ₹2166.60 | ₹2201.80 | 12.12K (Cr) | |
| ₹2160.00 | ₹2184.00 | ₹2133.10 | ₹2169.60 | 13.54K (Cr) | |
| ₹2205.30 | ₹2245.00 | ₹2132.00 | ₹2143.60 | 28.73K (Cr) | |
| ₹2250.00 | ₹2292.40 | ₹2192.10 | ₹2217.90 | 90.92K (Cr) | |
| ₹2214.20 | ₹2250.80 | ₹2181.50 | ₹2236.10 | 1.41L (Cr) | |
| ₹2208.20 | ₹2225.00 | ₹2060.50 | ₹2200.80 | 3.55L (Cr) | |
| ₹2175.00 | ₹2246.90 | ₹2150.00 | ₹2197.20 | 2.63L (Cr) | |
| ₹2093.40 | ₹2107.50 | ₹2054.80 | ₹2093.20 | 9.81K (Cr) | |
| ₹2100.00 | ₹2108.60 | ₹2056.70 | ₹2071.40 | 8.42K (Cr) | |
| ₹2121.00 | ₹2150.40 | ₹2090.80 | ₹2100.10 | 12.08K (Cr) |
CORONA Remedies Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹2060.00 | ₹2292.40 | ₹2020.20 | ₹2201.80 | +6.88% | |
| ₹2147.70 | ₹2192.80 | ₹2041.00 | ₹2050.30 | -4.54% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
CORONA Remedies Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
CORONA Remedies Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CORONA across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Conservative Debt Levels (D/E: 0.19)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (35.49x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (69.00%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
3 factors identified
Premium Valuation Risk (P/E: 67.04x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
High Price-to-Book Ratio (17.86x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Liquidity Concerns (Current Ratio: 0.96)
Observation: Current assets may not adequately cover short-term liabilities.
Analysis: Current ratio <1.0 raises working capital concerns.
CORONA Remedies Limited vs Sector Peers
CORONA Remedies Limited Quarterly Performance
Latest quarterly metrics for CORONA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
N/A
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
CORONA Remedies Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CORONA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
CORONA Remedies Limited Financial Statements
Annual income statement, balance sheet and cash flow for CORONA Remedies Limited (CORONA) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for CORONA Remedies Limited
About CORONA (CORONA Remedies Limited)
CORONA Remedies Limited (CORONA) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Unknown Industry sector with a... current market capitalisation of ₹13.34K (Cr). The debt-to-equity ratio stands at 0.19, reflecting the company's capital structure. Investors tracking CORONA share price can monitor key metrics including P/E ratio, promoter holding of 69.00%, and quarterly earnings growth.
Company Details
CORONA Share Price: Frequently Asked Questions
What is the current share price of CORONA Remedies Limited?
CORONA Remedies Limited (CORONA) trades at ₹2181.50 on NSE. Market cap ₹13.34K (Cr). Educational data only.
What is the P/E ratio of CORONA Remedies Limited?
CORONA Remedies Limited has a P/E of 67.04x vs industry average N/Ax.
What is the Bull Run score for CORONA Remedies Limited?
CORONA Remedies Limited has a Bull Run score of 0/100 based on 25+ financial parameters.
Does CORONA Remedies Limited pay dividends?
CORONA Remedies Limited has a dividend yield of N/A. Past dividends don't guarantee future payments.
What is the ROE of CORONA Remedies Limited?
CORONA Remedies Limited has ROE of N/A. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of CORONA Remedies Limited?
CORONA Remedies Limited has debt-to-equity of 0.19.
Is CORONA Remedies Limited a good investment?
Bull Run gives CORONA Remedies Limited a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.